Researchers evaluated the association of psoriasis and psoriatic arthritis with inflammatory bowel disease and other gastrointestinal illnesses.
Researchers evaluated the use of TNFis vs methotrexate in reducing the risk for progression to psoriatic arthritis in patients with psoriasis.
Researchers evaluated the long-term safety and tolerability of ixekizumab in adults with psoriasis, psoriatic arthritis and axial spondyloarthritis.
A subset of patients at risk for Alzheimer disease because of systemic inflammation may benefit from receiving a tumor necrosis factor (TNF) blocking agent.
Researchers conducted cost-effectiveness analyses to compare ixekizumab and secukinumab in psoriatic arthritis and moderate to severe plaque psoriasis.
Researchers analyzed dry eye and subclinical retinal abnormalities in a cohort of patients with psoriatic arthritis sine-psoriasis.
A slightly increased risk for developing certain cancers was seen in patients with psoriasis.
A more holistic approach to the care and treatment of patients with psoriasis and psoriatic arthritis has been found beneficial to patients.
Recently released guidelines from Japan outline the factors that may influence the choice of biologic agents for treatment in patients with psoriasis.
Apremilast used for the treatment of psoriasis or psoriatic arthritis is not associated with a high risk of incident treated depression, anxiety, or anxiety plus depression.
